Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacitidine + multi-TAA-specific cytotoxic T lymphocytes
- Development stage
- Unknown
- Lead developer
- Baylor College of Medicine
- Modality
- Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
This experimental combination immunotherapy, developed by Baylor College of Medicine, is designed for the treatment of relapsed or refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). The therapy consists of autologous cytotoxic T lymphocytes (CTLs) that are ex vivo expanded and trained to recognize five specific tumor-associated antigens (TAAs): NY-ESO-1, MAGEA4, PRAME, Survivin, and SSX. These antigens are frequently overexpressed in lymphoma cells but have restricted expression in normal tissues. The regimen incorporates azacitidine, a hypomethylating agent, which is administered to patients prior to the T-cell infusion. Azacitidine functions as an epigenetic modulator to upregulate the expression of the targeted TAAs on the surface of tumor cells, thereby enhancing the recognition and cytotoxic activity of the infused multi-TAA CTLs. This approach aims to overcome tumor immune evasion and improve clinical outcomes in patients who have failed standard therapies.
- Other names
- azacytidine + multi-TAA T cellsazacitidine + multi-TAA CTLsmulti-TAA specific cytotoxic T lymphocytes + azacitidinemulti-TAA CTLsTAA-CTLs
02
Targets
DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on azacitidine + multi-TAA-specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacitidine + multi-TAA-specific cytotoxic T lymphocytes.